Azitra Inc.

The past year has seen an increase in investment in biopharma companies following a couple of lean years, but the sector is not fully out of the woods yet. However, most industry leaders see funding

LEO Pharma A/S is not saying for certain that it has closed the door on its ointment formulation of isotretinoin, but said on 21 August the failure of TMB-001 to hit the primary endpoint in a Phase I

The market for initial public offerings in the US looks like it might be waking up from a month and a half nap with one biopharmaceutical company making it through the IPO window in mid-June and three

Bayer AG is stepping up its collaboration with medical dermatology company Azitra Inc. to advance the development of consumer health products that harness the human skin microbiome. Investment arm